Gilead Sciences Inc
0.00 | 0.00%
0.00 | 0.00%
30d. avg volume.
0.00 - 0.00
57.04 - 85.97
News and Commentary
Oxford, AstraZeneca Vaccine Produces Similar Immune Responses Across all Age Groups The coronavirus vaccine developed by the University of Oxford and the drugmaker AstraZeneca
Eli Lilly's Coronavirus Antibody Therapy Scores Emergency Use Authorization The U.S. Food and Drug Administration (F.D.A.) on Monday
Market Update: Benchmarks Fall to Weekly Losses as Sentiment Remains Uneasy Stocks rallied throughout Friday's session but ultimately closed mixed as investors continued to digest enduring stimulus talks and the final U.S. presidential debate between Pre...
Gilead's Remdesivir Becomes First F.D.A. Approved Coronavirus Treatment The U.S. Food and Drug Administration (F.D.A.) on Thursday approved Gilead Sciences's
Johnson & Johnson, Eli Lilly Coronavirus Trials Paused Due to Safety Concerns Two major large-scale clinical trials testing the safety and effectiveness of their respective coronavirus drugs have paused participant enrollments over safety concerns. The two...
Market Update: Stocks Gain on Positive Trump and Economic Stimulus News Stocks shook off Friday's losses and rose throughout Monday's session as investors were encouraged by President Donald Trump's improving health following his COVID-19 diagnosis a...
Regeneron Antibody Therapy Showing Promise A coronavirus antibody treatment being tested by Regeneron
U.S. Reputation Damaged Amongst Peers Due to Coronavirus Response The coronavirus pandemic has done more than damage the economy and public health in the United States: it has damaged the country's standing on the global stage. In a new 13-nati...